Aarey Drugs & Pharmaceuticals Gears Up for Q4 Reveal. Check Key Expectations Here

Posted by : Neeraj Pandey | Fri Mar 06 2026

Aarey Drugs & Pharmaceuticals Q4 FY26 results date has yet to be announced. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT. Aarey Drugs & Pharmaceuticals was listed on the National Stock Exchange (NSE) on 06-Aug-2021. Aarey Drugs & Pharmaceuticals share has its face value of 10 per share and its NSE symbol is AAREYDRUGS. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.

Table of Contents

Aarey Drugs & Pharmaceuticals Q4 Results 2026 Preview

Aarey Drugs & Pharmaceuticals Q4 FY26 revenue is expected to be around Stable Performance, representing a 6-9% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 7-10% YoY.
EBITDA to rise 7.50%.
Aarey Drugs & Pharmaceuticals is expected to show Stable Performance in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Aarey Drugs & Pharmaceuticals Share Performance

Over the past six months, Aarey Drugs & Pharmaceuticals share price has 14% by 6-9% to 73.9.
Moreover, over the past year, the stock has 25% by Up
Despite this weak short-term performance, Aarey Drugs & Pharmaceuticals stock has delivered a financially sound 120% return over the past 5 years.
As of today, 06-03-2026, the Aarey Drugs & Pharmaceuticals share price is trading at 73.9 per share.

Key Factors to Watch for Aarey Drugs & Pharmaceuticals Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Aarey Drugs & Pharmaceuticals

Aarey Drugs & Pharmaceuticals manufactures and supplies active pharmaceutical ingredients, intermediates, and specialty chemicals to domestic and international pharmaceutical companies, focusing on quality and reliability in its portfolio to cater to the pharmaceutical and healthcare industries.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Aarey Drugs & Pharmaceuticals is gear up to announce its Q4 FY26 results. Analysts expect 6-9% revenue growth, a 7-10% rise in PAT, and a 7.50% rise in EBITDA. Aarey Drugs & Pharmaceuticals focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Aarey Drugs & Pharmaceuticals Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.